Prognostic significance of pretreatment serum lactate dehydrogenase (LDH) in patients with osteosarcoma of the extremities

G. Bacci, P. Picci, D. Dallari, J. Neef, M. Avella, M. Orlandi, S. Ferrari, P. Caldora, M. Fontana

Research output: Contribution to journalArticlepeer-review

Abstract

The pretreatment serum lactate deydrogenase (LDH) levels of 457 patients with osteosarcoma of the extremities (65 metastatic and 392 localized at presentation) were examined to evaluate whether the levels of this enzyme had a clinical value in predicting the course of the disease. The percentage of patients with increased serum LDH at admission was significantly higher in the metastaic group than in the group of patients with localized disease (60% vs 29% : p <0.001). In the latter group, treated with adjuvant or neoadjuvant chemotherapy, the relapse rate was significantly higher in patients with an elevated serum LDH at admission than in those with normal levels (78% vs 42% : p <0.001). After surgery, in 101 out of 112 patients with elevated serum LDH at presentation the enzyme level normalized while in 11 it fell but did not reach a normal value. The rate of relapse in these two groups was respectively 77% and 91%. These data demonstrate that in osteosarcoma of value the extremities serum LDH levels have a definitive prognostic value and could also be used in evaluating the response to the therapy.

Original languageEnglish
Pages (from-to)386-390
Number of pages5
JournalCancer Journal (United States)
Volume2
Issue number11
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Prognostic significance of pretreatment serum lactate dehydrogenase (LDH) in patients with osteosarcoma of the extremities'. Together they form a unique fingerprint.

Cite this